sq 28603 has been researched along with milnacipran in 1 studies
Studies (sq 28603) | Trials (sq 28603) | Recent Studies (post-2010) (sq 28603) | Studies (milnacipran) | Trials (milnacipran) | Recent Studies (post-2010) (milnacipran) |
---|---|---|---|---|---|
35 | 0 | 0 | 13 | 1 | 5 |
Protein | Taxonomy | sq 28603 (IC50) | milnacipran (IC50) |
---|---|---|---|
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.9621 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.7046 | |
Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.125 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 6.1 | |
Transporter | Rattus norvegicus (Norway rat) | 0.065 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Morphy, R; Rankovic, Z | 1 |
1 review(s) available for sq 28603 and milnacipran
Article | Year |
---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |